Dr. Breanne Everett was 25 when she co-founded Orpyx Medical Technologies and developed the world’s first diabetic insole sensory substitution system, the SurroSense Rx, in an effort to save the limbs and lives of diabetic foot patients. As Orpyx’s Chief Executive Officer, Dr. Everett aims to make the company the world leader in innovating and developing wearable medical sensor-based technologies and sensory substitution systems, and help patients better cope with disease and improve their overall quality of life.
Named a “Top 40 under 40” in Alberta in 2012, Dr. Everett has been a Resident in Plastic and Reconstructive Surgery with Alberta Health Services since 2009. She has served as a Loran Award Assessor for the Loran Scholars Foundation, which identifies and supports exceptional young Canadians who demonstrate character, service and leadership. She is also a member of the Scientific Review Board of the Pedorthic Research Foundation of Canada.
Dr. Everett earned an MBA and an MD from the University of Calgary, and holds a BSc in Biochemistry from McGill University.